Remsima (infliximab biosimilar) for subcutaneous injection for managing rheumatoid arthritis (ES29)
Summary of the evidence on remsima (infliximab biosimilar) for subcutaneous injection for managing rheumatoid arthritis
Search results
5 results
-
-
Antimicrobial prescribing: imipenem with cilastatin and relebactam (ES30)
Summary of the evidence on antimicrobial prescribing: imipenem with cilastatin and relebactam
-
Antimicrobial prescribing: cefiderocol (ES31)
Summary of the evidence on antimicrobial prescribing: cefiderocol
-
Antimicrobial prescribing: delafloxacin for acute bacterial skin and skin structure infections (ES32)
Summary of the evidence on antimicrobial prescribing: delafloxacin
-
COVID-19 rapid evidence summary: Tocilizumab for COVID-19 (ES33)
ES33 Product overview The content of this evidence summary was up to date in January 2021. See summaries of product characteristics